The World Health Organisation has suspended testing malaria drug, Hydroxychloroquine, in COVID-19 patients due to safety concerns.
WHO Director-General, Tedros Adhanom Ghebreyesus, in a virtual press conference on Monday, said the decision came after the publication last week of a study indicating that using the drug on COVID-19 patients could increase their likelihood of dying.
Hydroxycholoroquine has been touted by United States President, Donald Trump, and others as a possible treatment for the disease. 
Trump had said he was taking the drug to help prevent infection.
“The executive group has implemented a temporary pause of the Hydroxychloroquine arm within the solidarity trial while the safety data is reviewed by the data safety monitoring board,” Ghebreyesus said.
